VKTX Stock — Viking Therapeutics Inc.

Viking Therapeutics Inc. (VKTX)

Updated October 16, 2026.

VKTX is a Stock. Total return is 180.9% over the past 11.5 years, 157.1 points behind SPY at 338.0%.

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with lead programs including VK2809 for non-alcoholic fatty liver disease (in Phase IIb trials) and several other candidates in earlier clinical stages targeting conditions such as hip fracture recovery, metabolic disorders, and rare genetic diseases. The company does not currently distribute to shareholders. Viking Therapeutics is headquartered in San Diego, California, and appeals primarily to investors seeking exposure to early-stage drug development with a focus on metabolic disease treatment.

VKTX performance versus SPY

Price and return data through 2026-10-16.

Total return is 180.9% over the past 11.5 years, 157.1 points behind SPY at 338.0%. Over the past year its total return — price change plus distributions reinvested — is -27.5%. Its deepest 1-year drawdown was 40.3%.

VKTX key facts

Asset type

Stock

Asset class

Equity

Inception date

04/29/2015

Distribution frequency

None

Last close

$25.17 (as of 2026-10-16)

Market cap

$3,200,749,368

Average volume

7570900.0

Beta

0.648

Payout ratio

0.0%

EPS

$-4.46

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VKTX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 40.3%.

Who may consider VKTX — and who may not

It is a weaker fit for investors who need monthly cash flow (VKTX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on VKTX

• All tickers starting with V

Tagged: Healthcare.

Frequently asked questions